Italian intersociety consensus on DOAC use in internal medicine.

scientific article published on 13 February 2017

Italian intersociety consensus on DOAC use in internal medicine. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S11739-017-1628-6
P2888exact matchhttps://scigraph.springernature.com/pub.10.1007/s11739-017-1628-6
P698PubMed publication ID28191610

P50authorFrancesco VioliQ37834358
Domenico PriscoQ43281338
Anna FalangaQ54574948
Walter AgenoQ56563198
Pasquale PignatelliQ57057602
Mauro SilingardiQ57076751
Giovanni DaviQ64541371
Francesco DentaliQ88396220
Gualtiero PalaretiQ91131655
P2093author name stringArmando D'Angelo
Francesca Santilli
Raimondo De Cristofaro
Antonella Tufano
Giovanni Di Minno
Cecilia Becattini
Gualberto Gussoni
Luca Masotti
Roberto M Santi
FADOI (Federation of Associations of Hospital Doctors on Internal Medicine)
SIMI (Italian Society of Internal Medicine)
SISET (Italian Society for the Study of Haemostasis and Thrombosis)
P2860cites workPeri-procedural management of patients taking oral anticoagulantsQ26801859
Direct oral anticoagulants: efficacy and safety in patient subgroupsQ27023677
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic eventsQ28080616
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjectsQ28247385
Idarucizumab for Dabigatran ReversalQ28263802
Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic reviewQ33468803
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology CoQ34093427
Apixaban with antiplatelet therapy after acute coronary syndromeQ34202772
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm SocietyQ34412804
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel ReportQ34513594
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteersQ34615829
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillationQ34651051
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing proceduresQ34683960
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysisQ35187005
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic reviewQ35559027
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesQ35752584
Chronic kidney disease: the global challengeQ36017142
New oral anticoagulants and the cancer patient.Q37519054
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.Q37552621
How I treat anticoagulated patients undergoing an elective procedure or surgeryQ38038988
The promise of novel direct oral anticoagulantsQ38041803
The laboratory and the direct oral anticoagulantsQ38097025
Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderlyQ38124014
Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.Q38129707
New oral anticoagulants in practice: pharmacological and practical considerationsQ38180988
Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring?Q38219531
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.Q38221642
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trialsQ38223081
Stroke prevention in patients with atrial fibrillation and renal dysfunctionQ38223517
Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysisQ38248341
Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrateQ38420791
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trialQ38469560
Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisalQ38543288
Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure: Systematic Review and Meta-Analysis of Randomized Trials.Q38719983
When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.Q38748850
Recent advances in antidotes for direct oral anticoagulants: their arrival is imminentQ39220291
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa InhibitorsQ41501792
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.Q41968675
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wardsQ42791455
In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studiesQ43235385
Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registryQ45841050
Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: the ATA AF studyQ45860268
Appropriateness of antithrombotic prophylaxis in the oldest old with non-valvular atrial fibrillation: ARAPACIS and REPOSI.Q45879103
Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.Q45884499
Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registryQ46719193
Extended use of dabigatran, warfarin, or placebo in venous thromboembolismQ46848170
Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.Q50934656
Rivaroxaban induced liver injury: A cholestatic pattern.Q52983227
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism.Q53038051
The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study.Q53166156
Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?Q54736318
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillationQ57626444
Decision making for oral anticoagulants in atrial fibrillation: The ATA-AF studyQ57628694
High plasma levels of factor VIII and the risk of recurrent venous thromboembolismQ74197149
Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolismQ77499876
6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIIIQ79642715
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assayQ82070566
The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein SQ83275741
In vitro and in vivo P-glycoprotein transport characteristics of rivaroxabanQ83942064
Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitorQ83943517
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinuxQ84039953
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndromeQ84968518
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA)Q84985096
Use of PER977 to reverse the anticoagulant effect of edoxabanQ85912324
Real-world variability in dabigatran levels in patients with atrial fibrillation: replyQ86953377
Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levelsQ87055126
The perioperative management of new direct oral anticoagulants: a question without answersQ87082444
Perioperative Management of Dabigatran: A Prospective Cohort StudyQ87294444
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteersQ87842081
New oral anticoagulants in patients with atrial fibrillation - Authors'replyQ88225137
P433issue3
P921main subjectinternal medicineQ11180
P304page(s)387-406
P577publication date2017-02-13
P1433published inInternal and emergency medicineQ26842320
P1476titleItalian intersociety consensus on DOAC use in internal medicine.
P478volume12

Reverse relations

cites work (P2860)
Q88764009Cardiac tamponade due to apixaban therapy in patient with unknown pericardial hemangioma
Q50002162Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.
Q90364741Determinants of health-related quality of life: a cross-sectional investigation in physician-managed anticoagulated patients using vitamin K antagonists
Q90140495Direct oral anticoagulants in factor VII deficiency patient
Q52676289Direct oral anticoagulants: what can we learn?
Q88564872Drug plasma level measurement in management of severe bleeding during direct oral anticoagulant treatment: case report and perspective
Q48299993ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations
Q63242297Estimating renal function in patients with atrial fibrillation: which dose of direct oral anticoagulants?
Q38635568Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?
Q52665386Intracranial hemorrhage in anticoagulated patients with mild traumatic brain injury: significant differences between direct oral anticoagulants and vitamin K antagonists.
Q48627362Is it reasonable to use a lower DOAC dose in some patients with VTE? NO.
Q36413874Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
Q56381361Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry
Q51742474Multidisciplinary approach to the management of patients with pulmonary embolism and deep vein thrombosis: a consensus on diagnosis, traditional therapy and therapy with rivaroxaban.
Q89338753NOAC in "real world" patients with atrial fibrillation in Italy: results from the ISPAF-2 (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study
Q57056338Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer
Q91978190Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
Q50001981The involvement of pharmacies in the screening of undiagnosed atrial fibrillation.
Q56384852The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures

Search more.